Furneri, G., Santoni, L., Ricella, C., & Prosperini, L. (2019). Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC.
Chicago-Zitierstil (17. Ausg.)Furneri, Gianluca, Laura Santoni, Chiara Ricella, und Luca Prosperini. Cost-effectiveness Analysis of Escalating to Natalizumab or Switching Among Immunomodulators in Relapsing-remitting Multiple Sclerosis in Italy. BMC, 2019.
MLA-Zitierstil (9. Ausg.)Furneri, Gianluca, et al. Cost-effectiveness Analysis of Escalating to Natalizumab or Switching Among Immunomodulators in Relapsing-remitting Multiple Sclerosis in Italy. BMC, 2019.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.